What is Raymond James’ Estimate for TSE:GUD Q4 Earnings?

Knight Therapeutics Inc. (TSE:GUD) – Analysts at Raymond James issued their Q4 2025 EPS estimates for Knight Therapeutics in a research report issued on Thursday, March 20th. Raymond James analyst M. Freeman forecasts that the company will earn $0.01 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.04 EPS.

Several other equities analysts have also recently weighed in on the company. Research Capitl upgraded Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 11th. Canaccord Genuity Group downgraded Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 21st. Finally, Stifel Nicolaus upped their price target on Knight Therapeutics from C$6.25 to C$7.45 and gave the company a “buy” rating in a research report on Tuesday. One research analyst has rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of C$7.48.

Knight Therapeutics Stock Up 0.7 %

Knight Therapeutics stock opened at C$6.01 on Monday. The firm has a market capitalization of C$607.91 million, a price-to-earnings ratio of -20.06, a P/E/G ratio of -1,013.50 and a beta of 0.50. The firm has a 50 day simple moving average of C$5.71 and a 200 day simple moving average of C$5.59. Knight Therapeutics has a 1-year low of C$5.09 and a 1-year high of C$6.45. The company has a current ratio of 3.36, a quick ratio of 1.79 and a debt-to-equity ratio of 7.52.

Insider Transactions at Knight Therapeutics

In other news, insider Sime Armoyan sold 2,500,000 shares of the business’s stock in a transaction dated Friday, March 21st. The stock was sold at an average price of C$6.30, for a total transaction of C$15,750,000.00. Over the last quarter, insiders have sold 3,143,300 shares of company stock valued at $19,733,740. 45.62% of the stock is currently owned by company insiders.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.